Navigation Links
Phase II Results of COL-144 Presented at European Headache and Migraine Trust International Congress 2008
Date:9/6/2008

Results Demonstrate Safety and Efficacy of First-in-Class Neurally Acting

Anti-Migraine Agent (NAAMA) for the Treatment of Acute Migraine

LONDON, Sept. 6 /PRNewswire/ -- CoLucid Pharmaceuticals, Inc., an innovative biotechnology company focusing on therapies for central nervous system disorders, announced Phase II results of its lead compound COL-144 in the treatment of acute migraine. Results demonstrated that COL-144 was safe and effective in relieving migraine headaches. COL-144 is a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA), which unlike triptans, exhibits anti-migraine activity without causing vasoconstriction. COL-144 is a highly potent and selective 5HT1F receptor agonist. The studies were presented in poster presentations at the European Headache and Migraine Trust International Congress 2008 in London, Sept. 4-7, 2008.

"In the Phase II study, the majority of patients experienced migraine relief 20 to 40 minutes after dosing and COL-144 was generally well-tolerated," Alison Pilgrim, BM, BCh, DPhil, chief medical officer at CoLucid, said. "The study indicates that COL-144 may be a treatment option for all patients including those who don't respond to or are contraindicated for the current standard of care."

The randomized, double-blind study evaluated 130 migraine patients. Patients were not on prophylaxis and received 2.5 to 45 mg of COL-144 or placebo as an intravenous infusion over 20 minutes as first-line treatment of an acute migraine attack. The primary end-point parameter was headache response, defined as a reduction in headache severity from moderate to severe at baseline to mild or no headache at two hours after initiation of infusion of study drug.

A higher proportion of patients showed a headache response at two hours post dose in the 10 mg, 20 mg, 30 mg and 45 mg groups compared to placebo (54.2 to 75% vs. 45.2%) with a statistically significant linear association between response rates and dose levels (p= 0.0126). The adaptive study design used could identify doses giving a headache response in 50-75% of patients. It did not explore the maximum possible efficacy of the drug.

COL-144 was generally well-tolerated with no serious adverse events or withdrawals due to non-serious adverse events. The most common adverse event was paresthesia, which was usually mild and transient, resolving rapidly after cessation of the infusion. No patient reported triptan-like chest symptoms in relation to the COL-144 infusion. No clinically significant changes were seen in vital signs or ECG parameters.

"We identified doses of 20 mg and higher as doses of interest for further evaluation in future studies, and we plan to continue the clinical development of COL-144, using an oral formulation," added Dr. Pilgrim.

About CoLucid Pharmaceuticals, Inc.

CoLucid Pharmaceuticals was founded in December 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatment for central nervous system (CNS) disorders. The company's pipeline includes COL-144, a novel treatment for migraine headache, and a conjugated stigmine platform that has generated a series of preclinical candidates for the treatment of sleep/wake disorders, chronic pain, Alzheimer's disease and psychiatric disorders. For more information, please visit CoLucid at http://www.colucid.com.


'/>"/>
SOURCE CoLucid Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 23, 2017 Report analyzes the ... provides separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Latin ... forecasts are provided for the period 2015 through 2022. Also, ... data and analytics are derived from primary and secondary research. ...
(Date:2/24/2017)... ITL Limited, ( ASX : ITD ), une société de ... excellents résultats semestriels clos le 31 décembre 2016 par ... « Résultats et mise à jour sur la croissance biomédicale ... Faits marquants Bénéfice ... hausse de 104 %) Bénéfice par action ...
(Date:2/24/2017)... -- This report analyzes the worldwide markets for Chiral Technology ... Products: Intermediates, Analytical, and Others. The End Use markets ... The report provides separate comprehensive analytics for the US, ... , and Rest of World. Annual estimates and forecasts ... a six-year historic analysis is provided for these markets. ...
Breaking Medicine Technology:
(Date:2/24/2017)... , ... February 24, 2017 , ... With ProGlass Prism ... Pro X . Users have total control over position, rotation, distortion, edge softness, edge ... within Final Cut Pro X. , With ProGlass Prism users are given the tools ...
(Date:2/24/2017)... Farifax, VA (PRWEB) , ... February 24, 2017 , ... ... winners for excellence in radiology marketing programs at the annual Building Better ... the Worthington Renaissance Fort Worth Hotel in Fort Worth, Texas. Nine awards are given ...
(Date:2/23/2017)... ... February 23, 2017 , ... On February 22, 2017 the ... to withdraw previous guidance issued by the Obama Administration requiring schools to ... May 2016 by the Obama Administration came in response to a growing number ...
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., ... From Not to Hot,” which will begin airing on February 24, 2017. The show ... from the 2012 reality television series, “Here Comes Honey Boo Boo.” The earlier series ...
(Date:2/23/2017)... ... , ... Dr. David Mahon leads Siena Dental, a comprehensive dental practice located ... 2017 Top Patient Rated Henderson Dentist by Find Local Doctors earlier this ... and dentists who have earned high ratings and superior patient reviews from multiple credible ...
Breaking Medicine News(10 mins):